about
Anti-human herpesvirus 6A/B IgG correlates with relapses and progression in multiple sclerosisMHC2TA mRNA levels and human herpesvirus 6 in multiple sclerosis patients treated with interferon beta along two-year follow-up.Role of the human endogenous retrovirus HERV-K18 in autoimmune disease susceptibility: study in the Spanish population and meta-analysis.Human endogenous retrovirus HERV-Fc1 association with multiple sclerosis susceptibility: a meta-analysisMultiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion.Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder.Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease.HERV-W polymorphism in chromosome X is associated with multiple sclerosis risk and with differential expression of MSRV.Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in Madrid.Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab.Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.Influence of metyrapone treatment during pregnancy on the development and maturation of brain monoaminergic systems in the rat.Re: Errors in the editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670-1672].JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event.Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorder.Role of maternal corticosterone in the development and maturation of the aminoacidergic systems of the rat brain.CD46 expression and HHV-6 infection in patients with multiple sclerosis.Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study.Expression of human endogenous retrovirus HERV-K18 is associated with clinical severity in osteoarthritis patients.Herpesviruses and human endogenous retroviral sequences in the cerebrospinal fluid of multiple sclerosis patients.Human endogenous retrovirus-K (HML-2): a comprehensive reviewErratum: Molecular characteristics of Human Endogenous Retrovirus type-W in schizophrenia and bipolar disorderHerpesvirus active replication in multiple sclerosisHuman herpesvirus-6 and multiple sclerosis: relapsing-remitting versus secondary progressiveEnvironment-gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TANeutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up studyCD46 in a Spanish cohort of multiple sclerosis patients: genetics, mRNA expression and response to interferon-beta treatmentHuman herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patientsMHC2TA rs4774C and HHV-6A active replication in multiple sclerosis patientsSyncytin-1/HERV-W envelope is an early activation marker of leukocytes and is upregulated in multiple sclerosis patientsTechnical considerations in detection of HERV-K in amyotrophic lateral sclerosis: selection of controls and the perils of qPCRSafety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial
P50
Q28245682-162C8DDE-56FD-425B-A33D-1B7DD8B04611Q34421060-1CC9E274-A5CF-4E15-8DEB-7E766076D8A0Q34698295-9A2316B9-4EC6-46FD-8BE6-95CAE04550E4Q35110787-22162FED-4C58-43A9-BE60-C0F2E203FFA2Q36347638-DDDFA7FB-4B0A-4CEF-801C-463484170466Q36589670-3418700B-7063-450C-93BF-ECB2491D7E08Q36613374-46B21BC8-0A9F-418C-8F1A-7E4752B3059BQ37479915-AC06C358-5C8E-4BAE-B3F7-8639436093D6Q39159379-F7EB108F-C0C7-4B35-886E-AB651B5EB5EAQ40401876-3BA785DD-F676-45F2-BCAE-99091A67CE99Q40502531-B06AD5A3-C97B-452E-ABEE-82FBC0415CA4Q40938497-69C7B02B-A059-4900-A46D-22E10D266DE7Q43298317-52C44439-0089-4F01-B5CA-E5170B6A9304Q45026040-71D6237E-7235-4A37-9512-2F0A2A7C8E12Q45403289-D5E7AEAC-74CE-4886-8F95-ACD16CFAE4AEQ46262885-53D231E4-D542-4114-B669-C5F250CDFEACQ46985888-6DF83005-8B9E-470C-86AF-9A91D067B565Q47761537-958F55D6-DEB4-4DBC-A40F-D7FA7AFD7C5EQ48585445-869913AD-DE8D-4DBA-A912-6034EB3F60FEQ51004439-B3A8CD76-1EF1-44B5-A9BF-743A97CFD877Q54527978-891447D5-9E93-48E9-90FD-899030E91E55Q57466814-63908BDA-C547-4F0C-85CE-88E5728B2162Q57700347-B1833039-C776-46A6-8A17-6FF43D26943AQ63197940-758A0D9C-414F-46FC-8900-86E36D76A34BQ80427530-19E790A4-7D4A-41D4-A5BD-8D759BFA9342Q80747633-D0EBA938-93E9-49D3-9276-3B8984376AECQ82405020-41BC7234-17A2-47D2-902D-FCBD7FFD036AQ82991720-BD4AAFB5-3DFD-41B6-90F6-42E657B72D7BQ83960058-B66A4B0C-14D2-4529-9AD4-02047F852E01Q84360520-E0D7E67E-D77B-4BD8-9962-5B2945A97E0BQ89506034-E68C771F-D3EA-4C7C-9EAD-5EDFCD21AD42Q91590773-D53663B3-1337-4843-B358-C99F32FB0F83Q91717096-A2F0B934-5437-497F-B400-65E4D6464D67
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Marta García-Montojo
@en
Marta García-Montojo
@nl
type
label
Marta García-Montojo
@en
Marta García-Montojo
@nl
prefLabel
Marta García-Montojo
@en
Marta García-Montojo
@nl
P31
P496
0000-0003-0664-3480